Holen Sie sich die Stockscreener-App
2.71
4.58%
-0.13
Handel nachbörslich:
2.75
0.04
+1.48%
Schlusskurs vom Vortag:
$2.84
Offen:
$2.82
24-Stunden-Volumen:
158.07K
Relative Volume:
0.12
Marktkapitalisierung:
$13.53M
Einnahmen:
$14.50M
Nettoeinkommen (Verlust:
$-15.41M
KGV:
-3.8169
EPS:
-0.71
Netto-Cashflow:
$-13.04M
1W Leistung:
-15.58%
1M Leistung:
+1.50%
6M Leistung:
+18.34%
1J Leistung:
-32.92%
1-Tages-Spanne:
$2.70
$2.94
1-Wochen-Bereich:
$2.70
$3.25
52-Wochen-Spanne:
$1.91
$48.79
Vivos Therapeutics Inc Stock (VVOS) Company Profile
Firmenname
Vivos Therapeutics Inc
Sektor
Branche
Telefon
(866)908-4867
Adresse
7921 SOUTHPARK PLAZA,, LITTLETON
Vergleichen Sie VVOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| VVOS | 2.71 | 13.53M | 14.50M | -15.41M | -13.04M | -0.71 |
| ABT | 117.36 | 202.64B | 41.22B | 5.77B | 6.49B | 2.94 |
| SYK | 389.40 | 150.72B | 21.97B | 3.59B | 3.21B | 6.74 |
| BSX | 90.45 | 133.82B | 15.91B | 1.79B | 1.89B | 0.82 |
| MDT | 87.59 | 112.98B | 32.58B | 3.93B | 5.15B | 2.71 |
| EW | 69.89 | 40.52B | 6.60B | 4.16B | 490.10M | 2.34 |
Vivos Therapeutics Inc Aktie (VVOS) Neueste Nachrichten
Vivos Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q3 2024 Earnings Call Transcript - Insider Monkey
ARMISTICE CAPITAL, LLC Acquires New Stake in Vivos Therapeutics Inc - GuruFocus.com
Vivos Therapeutics Reports Revenue Growth and Strategic Milestones - TipRanks
Vivos Therapeutics Inc (VVOS) Quarterly 10-Q Report - Quartzy
Vivos Therapeutics eyes positive cash flow as it continues cost-reduction success in Q3 - Proactive Investors USA
Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update - The Manila Times
Vivos Therapeutics Q3 Revenue Jumps 17% as FDA Approves Pediatric OSA Treatment | VVOS Stock News - StockTitan
Vivos Therapeutics Inc (VVOS) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call - The Manila Times
Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely - Simply Wall St
Vivos Therapeutics’ stock soars as sleep apnea device gets regulatory clearance - MSN
Vivos Therapeutics Secures FDA Clearance for Pediatric OSA Device, secures new AMA CPT Codes - Proactive Investors Australia
Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM - Yahoo Finance
Vivos Granted Reimbursement Codes for Oral Appliances for OSA - Sleep Review
Vivos secures new AMA medical codes for OSA devices - Investing.com
Pre-Market Momentum Builds For Vivos Therapeutics (VVOS) Following Key Developments - Stocks Telegraph
Vivos secures new AMA medical codes for OSA devices By Investing.com - Investing.com South Africa
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association - The Manila Times
Vivos Therapeutics wins approval for streamlined insurance reimbursement for sleep apnea treatment - Proactive Investors UK
Balance Sheet Insights: Vivos Therapeutics Inc (VVOS)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Stock Market Recap: Vivos Therapeutics Inc (VVOS) Concludes at 3.08, a -4.35 Surge/Decline - The Dwinnex
Vivos surges on FDA nod for pediatric sleep apnea device - MSN
You might want to take a look at Vivos Therapeutics Inc (VVOS) now - SETE News
Vivos Therapeutics announces $4.3 million stock sale By Investing.com - Investing.com Canada
Vivos Therapeutics announces $4.3 million stock sale - Investing.com
VVOS’s price-to-cash ratio: How it affects the stock’s valuation. - US Post News
Vivos Therapeutics Shares Drop 27% After Pricing of Common Stock Offering - MarketWatch
Why Vivos Therapeutics (VVOS) Stock Is Down 25% Today - Benzinga
Nasdaq Surges 400 Points; US Jobless Claims Fall To 219,000 - Benzinga
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - StockTitan
Vivos Therapeutics raises $4.3 from institutional investors - Proactive financial news
Nvidia, T-Mobile US, Vivos Therapeutics, SoFi Technologies, Tesla: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Vivos Therapeutics surges on FDA approval for youth sleep apnea treatment device - Mugglehead
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring - ForexTV.com
S&P 500 Industrials [Sector] (SRIN) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX 60 Equal Weight Index (TXEW) QuotePress Release - The Globe and Mail
TSX Metals and Mining Capped Index (TTMN) QuotePress Release - The Globe and Mail
TSX Cannabis Index (XCAN) QuotePress Release - The Globe and Mail
Company’s Banking Shares: Up -92.74% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle
Vivos Therapeutics rises on FDA approval for pediatric sleep apnea device - XM
What's Going On With TG Therapeutics Stock Wednesday? - Benzinga
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children - Benzinga
Vivos Therapeutics Shares Rally on FDA Clearance for Pediatric Sleep Apnea Treatment - MarketWatch
Vivos Therapeutics’ oral device approved by FDA for pediatric sleep apnea treatment - Proactive Investors UK
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Vivos (VVOS) Stock Rallies In Pre-Hours Trading Following Key Regulatory Approval - Stocks Telegraph
Vivos gains FDA nod for child OSA treatment device - Investing.com
Vivos receives FDA 510k clearance to treat pediatric sleep apnea, snoring - TipRanks
Target Hospitality Corp. Forecasted to Post FY2025 Earnings of $0.39 Per Share (NASDAQ:TH) - Defense World
Finanzdaten der Vivos Therapeutics Inc-Aktie (VVOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
0.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):